xx
Testing Microsatellite-Instability for Response to Chemotherapy ....... 265
Pharmacogenetics of Cancer Chemotherapy ............................................ 266
CYP 1A2 ............................................................................................... 266
Thiopurine Methyltransferase ............................................................... 267
Dihydropyrimidine Dehydrogenase ...................................................... 267
UGT1A1 Test as Guide to Irinotecan Therapy ..................................... 268
Role of Computational Models in Personalized Anticancer Therapy ....... 269
A Computational Model of Kinetically Tailored Treatment ................. 269
Mathematical Modeling of Tumor Microenvironments ....................... 270
Modeling Signaling Pathways to Reposition Anticancer Drugs ........... 270
Therapy Resistance in Cancer ................................................................... 271
Mechanism of Therapy Resistance in Cancer ....................................... 271
Detection of Drug Resistance ............................................................... 273
Management of Drug Resistance in Cancer .......................................... 274
Personalized Therapy of Cancer Metastases ............................................. 277
Personalized Management of Cancers of Various Organs ........................ 278
Personalized Management of Brain Tumors ......................................... 278
Personalized Management of Breast Cancer ........................................ 292
Personalized Management of Ovarian Cancer ...................................... 318
Personalized Management of Head and Neck Cancer .......................... 325
Personalized Management of Hematological Malignancies ................. 326
Personalized Management of Lymphomas ........................................... 334
Personalized Management of Gastrointestinal Cancer ......................... 337
Personalized Management of Liver Cancer .......................................... 345
Personalized Management of Lung Cancer .......................................... 346
Personalized Management of Malignant Melanoma ............................ 355
Personalized Management of Pancreatic Cancer .................................. 358
Personalized Management of Prostate Cancer ...................................... 360
Personalized Management of Thyroid Cancer ...................................... 364
Future of Cancer Therapy ......................................................................... 364
Challenges for Developing Personalized Cancer Therapies ................. 365
Cancer Genome Atlas ........................................................................... 365
COLTHERES Consortium .................................................................... 366
Computer and Imaging Technologies for Personalizing
Cancer Treatment .................................................................................. 366
Genomic Cancer Care Alliance ............................................................. 367
Integrated Genome-Wide Analysis of Cancer
for Personalized Therapy ...................................................................... 367
International Cancer Genome Consortium ........................................... 368
National Cancer Institute of US ............................................................ 369
PREDICT Consortium .......................................................................... 370
Quebec Clinical Research Organization in Cancer ............................... 370
References ................................................................................................. 371Contents